The present review is an update of the research and development efforts regarding the use
of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical …

Lung cancer is the deadliest cancer worldwide. Tissue biopsy is currently employed for the
diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive …

Background Sepsis is a leading cause of death in intensive care units (ICUs), but outcomes
of individual patients are difficult to predict. The recently developed clinical metabolomics …

At the root of the so-called precision medicine or precision oncology, which is our focus
here, is the hypothesis that cancer treatment would be considerably better if therapies were …

Metabolomics encompasses the systematic identification and quantification of all metabolic
products in the human body. This field could provide clinicians with novel sets of diagnostic …

As a rapid, label-free, non-destructive analytical measurement requiring little to no sample
preparation, Raman spectroscopy shows great promise for liquid biopsy cancer detection …

Introduction Lung cancer continues to be the leading cause of cancer-related mortality
worldwide. Early detection has proven essential to extend survival. Genomic and proteomic …

Detection of metabolic disturbances in lung cancer (LC) has the potential to aid early
diagnosis/prognosis and hence improve disease management strategies through reliable …

The objective of this research is to use metabolomic techniques to discover and validate
plasma metabolite biomarkers for the diagnosis of early-stage non-small cell lung cancer …

Purpose Surface-enhanced Raman scattering (SERS) spectroscopy on serum and other
biofluids for cancer diagnosis represents an emerging field, which has shown promising …